SXTP vs. GOVX, EQ, EDSA, LPTX, MEIP, PRPH, GELS, ME, RLMD, and TRIB
Should you be buying 60 Degrees Pharmaceuticals stock or one of its competitors? The main competitors of 60 Degrees Pharmaceuticals include GeoVax Labs (GOVX), Equillium (EQ), Edesa Biotech (EDSA), Leap Therapeutics (LPTX), MEI Pharma (MEIP), ProPhase Labs (PRPH), Gelteq (GELS), 23andMe (ME), Relmada Therapeutics (RLMD), and Trinity Biotech (TRIB). These companies are all part of the "pharmaceutical products" industry.
60 Degrees Pharmaceuticals vs.
GeoVax Labs (NASDAQ:GOVX) and 60 Degrees Pharmaceuticals (NASDAQ:SXTP) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, risk, valuation, earnings, community ranking, institutional ownership, analyst recommendations, profitability and media sentiment.
GeoVax Labs has a beta of 3.47, indicating that its stock price is 247% more volatile than the S&P 500. Comparatively, 60 Degrees Pharmaceuticals has a beta of 3.02, indicating that its stock price is 202% more volatile than the S&P 500.
In the previous week, GeoVax Labs and GeoVax Labs both had 1 articles in the media. GeoVax Labs' average media sentiment score of 0.00 beat 60 Degrees Pharmaceuticals' score of -1.50 indicating that GeoVax Labs is being referred to more favorably in the media.
60 Degrees Pharmaceuticals' return on equity of 0.00% beat GeoVax Labs' return on equity.
60 Degrees Pharmaceuticals has lower revenue, but higher earnings than GeoVax Labs. GeoVax Labs is trading at a lower price-to-earnings ratio than 60 Degrees Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
GeoVax Labs presently has a consensus target price of $11.10, indicating a potential upside of 988.24%. Given GeoVax Labs' stronger consensus rating and higher possible upside, equities analysts plainly believe GeoVax Labs is more favorable than 60 Degrees Pharmaceuticals.
GeoVax Labs received 29 more outperform votes than 60 Degrees Pharmaceuticals when rated by MarketBeat users. Likewise, 96.77% of users gave GeoVax Labs an outperform vote while only 4.76% of users gave 60 Degrees Pharmaceuticals an outperform vote.
6.1% of GeoVax Labs shares are held by institutional investors. Comparatively, 8.0% of 60 Degrees Pharmaceuticals shares are held by institutional investors. 1.2% of GeoVax Labs shares are held by company insiders. Comparatively, 10.3% of 60 Degrees Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Summary
GeoVax Labs beats 60 Degrees Pharmaceuticals on 10 of the 17 factors compared between the two stocks.
Get 60 Degrees Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for SXTP and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
60 Degrees Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:SXTP) was last updated on 5/22/2025 by MarketBeat.com Staff
Buy SXTP Stock Free SXTP Stock Alerts